A year ago, I embarked on an unexpected health-tech journey. With a conference trip looming, I prepped my arms not for a medical necessity, but for an experiment. After swabbing the skin with alcohol, I pressed two separate applicators—one for a Dexcom Stelo, another for an Abbott Lingo—against my arms. A sharp ka-thunk later, I was wearing two over-the-counter continuous glucose monitors (CGMs), devices designed to track blood sugar trends in real time. As a non-diabetic with historically normal A1C levels, I had no clinical reason for this. I was simply curious: could this technology, increasingly touted by wellness influencers and biohackers, offer benefits to someone without diabetes? What began as a brief trial spiraled into a year-long deep dive, filled with device testing, research, and consultations, all in pursuit of an answer.
CGMs represent a significant shift in personal health monitoring. Unlike traditional finger-prick tests that measure blood glucose directly, these sensors analyze the interstitial fluid just beneath the skin, providing a continuous stream of data on glucose fluctuations. Initially prescription-only and vital for Type 1 diabetes management, the landscape changed in 2024. Companies like Dexcom and Abbott now market CGMs directly to non-diabetics, prediabetics, and Type 2 diabetics not on insulin, sometimes rebranding them as "glucose biosensors."
The potential value for prediabetics and Type 2 diabetics is substantial. These conditions, often linked to insulin resistance, can sometimes be mitigated through early lifestyle changes. With an estimated 36 million Americans living with Type 2 diabetes and about 98 million with prediabetes, CGMs could empower many to understand how their diet directly impacts a metabolic condition.
However, the utility for non-diabetics remains a subject of intense debate. Despite this, a powerful push for widespread adoption is underway. From government health officials suggesting a future where everyone might wear one, to startups like Levels promoting CGMs as tools to combat "metabolic dysfunction," the technology is being positioned as the next frontier in health optimization. Proponents argue it offers individuals control and insight in a flawed healthcare system, allowing them to "biohack" their way to better health. Critics, including several medical experts, counter that robust evidence supporting use in non-diabetics is lacking.
This debate unfolds against a backdrop of a growing wellness industry obsessed with metabolic optimization. The trend has evolved from simple food logging to incorporating CGM data, with companies like January AI and Oura integrating glucose tracking and AI-driven insights into their apps. This convergence of wearable tech, diet culture, and the rising use of medications like GLP-1s frames CGM use as the logical evolution of fitness tracking.
"It’s predicted one in two Americans will have obesity by the year 2030," says Dr. Thomas Grace, a diabetes clinician who consulted on the Dexcom Stelo. "I think the most exciting thing... is the instant reward they get from understanding how food, activity, stress, and sleep affect their overall glucose health."
I am the precise demographic for this pitch: someone with a family history of Type 2 diabetes and a diagnosis of polycystic ovary syndrome (PCOS), which often involves insulin resistance. As a runner battling inconsistent energy levels, the promise of optimizing my nutrition and managing diabetes risk was compelling. Yet, the reality of constant monitoring brought its own complexities. Applying the devices became routine, though I grew hyper-aware of clothing choices to accommodate them. Even with perfect application, sensors could fail unpredictably, sometimes lasting only 48 hours—a reminder of the technology's imperfections.
Wearing a CGM around the clock is often described as invisible, but the psychological and data-driven footprint it leaves is anything but. For non-diabetics, the central question persists: does this constant stream of glucose data lead to meaningful health improvements, or does it fuel unnecessary anxiety in the pursuit of an optimized, yet elusive, biometric ideal? My year-long experiment left me with more questions than definitive answers, navigating the fine line between insightful health tool and a source of continuous, data-driven doubt.